Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Chipscreen-Biosciences"

3 News Found

NAFLD clinical trial activity catching up in China but lacks substantial domestic participation, says GlobalData
News | December 27, 2022

NAFLD clinical trial activity catching up in China but lacks substantial domestic participation, says GlobalData

China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.

Ascletis Pharma completes patient enrollment in clinical for cure of HIV infection
Drug Approval | September 16, 2022

Ascletis Pharma completes patient enrollment in clinical for cure of HIV infection

The objective of this study is to evaluate the efficacy of ASC22 (Envafolimab) combined with Chidamide on the viral reservoirs of latently infected cells in HIV patients.

Clinical study of PD-L1 antibody ASC22 for cure of HIV completes first patient dosing
Diagnostic Center | July 04, 2022

Clinical study of PD-L1 antibody ASC22 for cure of HIV completes first patient dosing

Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection

Latest Stories

Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr

Sigachi Industries signs MoU with Respilon Group

USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging